An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Pegcetacoplan in Patients with Transplant-associated Thrombotic Microangiopathy (TA-TMA) After Hematopoietic Stem Cell Transplantation (HSCT)
Sobi.PEGCET-201
Phase 2 other active
Quick answer
An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Pegcetacoplan in Patients with Transplant-associated Thrombotic Microangiopathy (TA-TMA) After Hematopoietic Stem Cell Transplantation (HSCT) for Transplant-associated Thrombotic Microangiopathy (TA TMA) is a Phase 2 program (other) at Swedish Orphan Biovitrum AB (publ) with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Swedish Orphan Biovitrum AB (publ)
- Indication
- Transplant-associated Thrombotic Microangiopathy (TA TMA)
- Phase
- Phase 2
- Modality
- other
- Status
- active